Physician profile
Matthew Jackson
NPI 1700535861
$1,439.22
in general payments reported to CMS, 2019-2025
19 companies · $533 in 2025
The $533 reported for 2025 was more than what 75% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $115 · 2023: $415 · 2024: $376 · 2025: $533.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,324.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,323.92 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $192.77 | 2022-2025 | Ozempic, Rybelsus |
| Novartis Pharmaceuticals Corporation | $185.24 | 2023-2025 | |
| Amgen INC. | $172.25 | 2024-2025 | Krystexxa, Otezla, Repatha |
| Abbvie INC. | $168.32 | 2023-2025 | |
| Stryker Corporation | $148.92 | 2025 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Astrazeneca Pharmaceuticals LP | $136.98 | 2023-2025 | Farxiga, Airsupra, Breztri |
| Horizon Therapeutics Plc | $79.65 | 2023 | Krystexxa |
| Dexcom, INC. | $58.49 | 2023-2024 | Dexcom G6 Transmitter |
| Lilly USA, LLC | $55.55 | 2022-2023 | Jardiance, Trulicity, Mounjaro |
| Phathom Pharmaceuticals, INC. | $44.76 | 2024-2025 | Voquezna |
| Sanofi-Aventis U.S. LLC | $42.45 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $28.82 | 2023 | Jardiance, Synjardy |
| Glaxosmithkline, LLC. | $22.44 | 2023 | Trelegy Ellipta |
| Abiomed | $21.40 | 2024 | Impella |
| Exact Sciences Corporation | $17.57 | 2025 | Cologuard Collection Kit |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Hologic Sales and Service, LLC | $17.45 | 2025 | Aptima |
| Medicem INC. | $17.04 | 2023 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.06 | 2025 | Xifaxan |
| Cvrx, INC. | $14.06 | 2024 | Barostim Neo System |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Matthew Jackson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.